Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 109 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Restless Legs Clear all
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Bupropion and Restless Legs Syndrome

NCT00621517
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Bupropion, Placebo
Drug
Lead sponsor
East Tennessee State University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Johnson City, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Jul 22, 2026, 10:01 AM EDT
Completed No phase listed Observational

Neuronal Ceroid Lipofuscinosis and Associated Sleep Abnormalities

NCT01966757
View directory record Official record
Conditions
Neuronal Ceroid Lipofuscinosis, Batten's Disease
Interventions
Not listed
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Jul 22, 2026, 10:01 AM EDT
Withdrawn Phase 4 Interventional

Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome

NCT00584246
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Pregabalin (Lyrica), Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Jul 22, 2026, 10:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects

NCT01411124
View directory record Official record
Conditions
Restless Legs Syndrome (RLS)
Interventions
gabapentin enacarbil, diphenhydramine, placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Jul 22, 2026, 10:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole

NCT00422994
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
ropinirole dosing for up to 28 days
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Jul 22, 2026, 10:01 AM EDT
Withdrawn Phase 1 Interventional

A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS

NCT02633657
View directory record Official record
Conditions
RLS
Interventions
HORIZANT 300 mg
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
13 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Redwood City, California • St Louis, Missouri • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Jul 22, 2026, 10:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Altered Brain GABA and Glutamate in Restless Legs Syndrome

NCT01109537
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Jul 22, 2026, 10:01 AM EDT
Terminated Phase 2 Interventional Results available

Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia

NCT02826681
View directory record Official record
Conditions
Restless Legs Syndrome (RLS)
Interventions
Injectafer® (Ferric Carboxymaltose - FCM), Placebo (Normal Saline)
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Lemon Grove, California • Fort Myers, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Jul 22, 2026, 10:01 AM EDT
Completed Phase 4 Interventional Results available

Switching From Oral Dopamine Agonists to Rotigotine

NCT01976871
View directory record Official record
Conditions
Restless Legs Syndrome, Ekbom Syndrome, Willis-Ekbom Disease
Interventions
Rotigotine
Drug
Lead sponsor
John Winkelman, MD, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Jul 22, 2026, 10:01 AM EDT
Terminated Phase 3 Interventional

Right to Left Cardiac Shunt Detection

NCT01773252
View directory record Official record
Conditions
Right to Left Shunt, Patent Foramen Ovale, Atrial Septal Defect
Interventions
Flow Detection System
Device
Lead sponsor
Cardiox Corporation
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2015 · Synced Jul 22, 2026, 10:01 AM EDT
Completed Phase 3 Interventional Results available

Placebo-Controlled Study to Investigate the Efficacy & Safety of Injectafer in the Treatment of RLS

NCT02397057
View directory record Official record
Conditions
Restless Legs Syndrome (RLS)
Interventions
Injectafer, Placebo
Drug · Other
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Mobile, Alabama • National City, California • Rancho Mirage, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Jul 22, 2026, 10:01 AM EDT
Recruiting No phase listed Observational

Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment

NCT06726785
View directory record Official record
Conditions
Restless Leg Syndrome (RLS)
Interventions
Not listed
Lead sponsor
HBC Immunology Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jul 22, 2026, 10:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist

NCT03218969
View directory record Official record
Conditions
Restless Legs Syndrome, Augmentation
Interventions
Ecopipam, Placebo
Drug
Lead sponsor
William Ondo, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 22, 2026, 10:01 AM EDT
Recruiting Not applicable Interventional

Blood Changes After Exercise in Restless Legs Syndrome

NCT06481176
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
12-Week RLS Exercise Program
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Jul 22, 2026, 10:01 AM EDT
Recruiting Not applicable Interventional

Peroneal Electrical Nerve Stimulation in Pregnancy for Restless Legs Syndrome

NCT07144631
View directory record Official record
Conditions
Restless Leg Disorder, Restless Leg Syndrome (RLS), Pregnancy, Sleep Disorder (Disorder)
Interventions
Peroneal Nerve Stimulation (PNS) Device
Device
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 22, 2026, 10:01 AM EDT
Completed Phase 2 Interventional Results available

Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome

NCT01498120
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
13 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Spring Hill, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Jul 22, 2026, 10:01 AM EDT
Completed Not applicable Interventional Results available

Extension Study Evaluating NTX100 Neuromodulation System for Medication-Refractory Primary RLS

NCT05196828
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
NTX100 Neuromodulation System
Device
Lead sponsor
Noctrix Health, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
San Leandro, California • Colorado Springs, Colorado • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 10:01 AM EDT
Completed Phase 3 Interventional

A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome

NCT00363857
View directory record Official record
Conditions
Restless Legs Syndrome (RLS), Restless Legs Syndrome
Interventions
Ropinirole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
49
States / cities
Alabaster, Alabama • Birmingham, Alabama • Jasper, Alabama + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Jul 22, 2026, 10:01 AM EDT
Completed No phase listed Observational

Comparison of Dialysis Therapies on Cognitive Function

NCT00597103
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Disease
Interventions
Cognitive Function Testing-10 Tests, Sleep Assessment Testing, Periodic Leg Movement Syndrome Assessment
Other
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Jul 22, 2026, 10:01 AM EDT
Terminated Phase 2Phase 3 Interventional

Safety and Efficacy of Rasagiline in Restless Legs Syndrome

NCT01192503
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
rasagiline, placebo (sugar pill)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
Pinellas Park, Florida • Augusta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Jul 22, 2026, 10:01 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)

NCT00133198
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Pramipexole
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
44
States / cities
Peoria, Arizona • Scottsdale, Arizona • Fountain Valley, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Jul 22, 2026, 10:01 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome

NCT00834327
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
aplindore MR tablets or Placebo
Drug
Lead sponsor
Neurogen Corporation
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
24
States / cities
Phoenix, Arizona • Tuscon, Arizona • Oceanside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2009 · Synced Jul 22, 2026, 10:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comprehensive Police Fatigue Management Program

NCT00246051
View directory record Official record
Conditions
Sleep Disorders, Sleep Apnea, Obstructive, Restless Legs Syndrome, Sleep Disorders, Circadian Rhythm, Sleep Initiation and Maintenance Disorders
Interventions
Sleep Hygiene Education, Expert-Led Sleep Disorders Screening and Treatment, Online Sleep Disorders Screening
Behavioral · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
683 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Jul 22, 2026, 10:01 AM EDT
Active, not recruiting No phase listed Observational

A Post-Market Study for Long-Term Effectiveness and Safety of the TOMAC System for RLS

NCT06076499
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
NTX100
Device
Lead sponsor
Noctrix Health, Inc.
Industry
Eligibility
21 Years and older
Enrollment
325 participants
Timeline
2023 – 2027
U.S. locations
7
States / cities
Downey, California • San Ramon, California • Newton, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 22, 2026, 10:01 AM EDT